N. Engl. J. Med. 383, 109–119 & 151–158 (2020)
Two studies show the potential of RNA-based gene-therapy approaches in the treatment of amyotrophic lateral sclerosis (ALS).
ALS is a neurodegenerative disease that in 10% of patients is caused by a mutation in the gene encoding superoxide dismutase 1 (SOD1), and targeting this gene is a therapeutic approach in development.
Mueller and colleagues use a microRNA directed against SOD1 (AAV-miR-SOD1) to target and reduce SOD1 expression in two patients with ALS. They find that the approach is safe and shows some clinical promise in one of the patients. In a phase 1/2 trial of 50 participants, the authors carry out intrathecal administration of an antisense oligonucleotide, tofersen, that mediates the degradation of SOD-1. The trial shows tofersen to be effective in reducing SOD-1 levels.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Stower, H. Opening the door to gene therapy for ALS. Nat Med 26, 1170 (2020). https://doi.org/10.1038/s41591-020-1029-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-020-1029-7